Search
Neogenomics Inc
NEOAdd to Watchlist
14.970USD
+0.380+2.60%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.95BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of Neogenomics Inc is 7.83, ranking 37 out of 75 in the Healthcare Providers & Services industry. The average price target is 13.00, with a high of 17.00 and a low of 5.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
15.056
Target Price
+3.19%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
68
Total
8
Median
9
Average
Company name
Ratings
Analysts
Neogenomics Inc
NEO
12
CVS Health Corp
CVS
29
Teladoc Health Inc
TDOC
27
HCA Healthcare Inc
HCA
26
Natera Inc
NTRA
23
Tenet Healthcare Corp
THC
23
1
2
3
...
14
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Neogenomics Inc's expected revenue for the next quarter?
Neogenomics Inc's expected revenue is 197.00M.
What is Neogenomics Inc's price target?
Analysts forecast that Neogenomics Inc's price target is USD 13.00, with the highest forecast at USD 17.00 and the lowest forecast at USD 5.00.
How have Neogenomics IncNEO's recent earnings per share performed?
The market expectation was USD -0.13, while Neogenomics IncNEO's earnings per share (EPS) for the previous quarter was USD -0.08. EPS for the next quarter is expected at USD 0.03.
What is the analyst rating for Neogenomics Inc?
Based on the ratings of Neogenomics Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.